Tukysa 150mg Tablet (Tucatinib)

Tukysa 150mg Tablet is a prescription-based targeted anticancer medicine used in the treatment of advanced or metastatic HER2-positive breast cancer & RAS wild-type, HER2-positive colorectal cancer that has previously been treated with standard chemotherapies. The active ingredient of the Tukysa is Tucatinib, which belongs to the drug class of tyrosine kinase inhibitors. It controls the growth & multiplication of cancer cells by inhibiting the function of abnormal HER2 protein. By inhibiting HER2 signaling, it helps decrease cancer cell division and progression. Tucatinib 150mg Tablet is given in a specific combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.

The tablet is taken orally and exactly as prescribed by the doctor. The tablet must be swallowed as whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. Tucatinib 150mg Tablet is given twice daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include diarrhea, nausea, vomiting, mouth sores, rash, decreased appetite, tiredness, and increased liver enzyme levels. A few patients can undergo severe side effects, including severe diarrhea, serious liver problems, and severe allergic reactions. Most of the Tucatinib 150mg tablet side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

Avoid grapefruit and grapefruit juice unless your doctor advises. The medicine may harm an unborn baby and should not be used during pregnancy. Patients must list all medicines, supplements, and herbal products that they are taking. The Tucatinib 150mg Tablet must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Head and neck cancer, kidney cancer, lung cancer, liver cancer, skin cancer

The human body shows undesired symptoms after taking Tukysa 150mg Tablet (Tucatinib). Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Tucatinib Tablet are mentioned below:
● Fever
● Fatigue
● Diarrhea
● Headache
● Weight gain
● Eye dryness
● Hemorrhage
● Muscles pain
● Breathlessness
● Abdominal pain
● Nausea & Vomiting
● Swelling in face, legs, and feet

Tucatinib 150mg Tablet (Tukysa) is a prescription-based anticancer drug that should be administered orally. Tukysa is taken orally with or without food as per the doctor's advice.

It is consumed at the same time each day for better results. It is recommended not to crush, chew, or split the tablet, take it as a whole.

● Shah, M., Wedam, S., Cheng, J., Fiero, M. H., Xia, H., Li, F., ... & Beaver, J. A. (2021). FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clinical Cancer Research, 27(5), 1220-1226.
● Okines, A. F., Curigliano, G., Mizuno, N., Oh, D. Y., Rorive, A., Soliman, H., ... & Pohlmann, P. R. (2025). Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nature medicine, 31(3), 909-916.
● Topletz-Erickson, A., Lee, A., Rustia, E. L., Sun, H., Mayor, J. G., Abdulrasool, L. I., ... & Endres, C. J. (2022). Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteer s. Clinical Pharmacokinetics, 61(10), 1417.
● Sirhan, Z., Thyagarajan, A., & Sahu, R. P. (2022). The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Medical Research, 9(1), 39.
● Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., ... & Winer, E. P. (2020). Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. New England Journal of Medicine, 382(7), 597-609.